KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 71 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $250,000 | -34.2% | 17,236 | -55.4% | 0.03% | -42.1% |
| Q2 2022 | $380,000 | +9.8% | 38,650 | +64.5% | 0.06% | +23.9% |
| Q1 2022 | $346,000 | +127.6% | 23,502 | +104.4% | 0.05% | +142.1% |
| Q4 2021 | $152,000 | -64.7% | 11,499 | -49.3% | 0.02% | -72.9% |
| Q4 2020 | $430,000 | +34.0% | 22,664 | -11.0% | 0.07% | +29.6% |
| Q3 2020 | $321,000 | +150.8% | 25,466 | +51.7% | 0.05% | +68.8% |
| Q1 2020 | $128,000 | -57.3% | 16,786 | -0.3% | 0.03% | -8.6% |
| Q4 2019 | $300,000 | +150.0% | 16,836 | +63.1% | 0.04% | +118.8% |
| Q3 2019 | $120,000 | -43.1% | 10,321 | +40.0% | 0.02% | -23.8% |
| Q1 2019 | $211,000 | – | 7,371 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |